8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Apr 29, 2020)

Filed April 29, 2020For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on April 29, 2020, to report its financial results for the first quarter ended March 31, 2020. The filing primarily serves to furnish a press release detailing these results, which is incorporated by reference. While the 8-K itself does not contain the detailed financial figures, it directs investors to the press release (Exhibit 99.1) for the specific operational and financial condition updates. This report is crucial for investors seeking the latest performance data of the company. Investors should refer to the furnished press release for comprehensive insights into the company's revenue, earnings, and any significant business developments that occurred during the first quarter of 2020. The filing also includes a standard forward-looking statements disclaimer, highlighting various risks and uncertainties that could impact future performance, including the evolving landscape of healthcare costs, regulatory changes, and the potential impact of public health crises like COVID-19.

Key Highlights

  • 1Elevance Health (Anthem, Inc.) reported its Q1 2020 financial results via an 8-K filing on April 29, 2020.
  • 2The primary content of the 8-K is a furnished press release (Exhibit 99.1) containing the company's financial results for the quarter ended March 31, 2020.
  • 3Investors are directed to the press release for detailed information on the company's operational performance and financial condition.
  • 4The filing includes a standard 'Forward-Looking Statements' section, cautioning investors about risks and uncertainties.
  • 5Key risks mentioned include the impact of large-scale medical emergencies (e.g., COVID-19), healthcare cost trends, regulatory changes (including the ACA), and competitive pressures.
  • 6The company also highlights risks related to its PBM business, litigation, data security, and operational systems.
  • 7No new financial statements or specific figures are presented directly within the 8-K filing itself; these are contained within the referenced press release.

Frequently Asked Questions

The specific financial results for the first quarter ended March 31, 2020, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to that document for comprehensive details.

The filing highlights several significant risks including the impact of public health emergencies like COVID-19, evolving healthcare costs and utilization, changes in federal and state regulations (including the ACA), competitive pressures, risks associated with their pharmacy benefit management (PBM) business, potential litigation, and the need to maintain and modernize information systems.

The information furnished in Item 2.02 and Exhibit 99.1 is generally not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. Unless expressly stated, this information will not be incorporated by reference into other SEC filings, such as those under the Securities Act of 1933.

This particular 8-K filing is primarily focused on reporting the company's first-quarter financial results through a press release. It does not appear to announce new strategic initiatives, mergers, acquisitions, or divestitures. For such information, investors should review the content of the furnished press release and other SEC filings.